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Outline 
• MassBiologics- A Unique UMass Asset 
 
• What Questions Do We Ask When Considering  
Developing A New Medicine 
 
• How Do We Develop A Medicine 
 
• How We Can Help You 
MassBiologics 
• Established in 1894 as collaboration between the 
Commonwealth’s Department of Public Health and Harvard 
University (became part of UMMS in 1997) 
• During a 120 year history MassBiologics has discovered and 
manufactured over 100 million doses of life saving medicines 
for the citizens of the Commonwealth and the world. 
• Product Discovery often addresses needs of populations 
where commercial market is limited.    
• Is the only non-profit, FDA-licensed manufacturer of 
vaccines and biologics in the United States.  
Mission 
To discover, develop, and manufacture biological 
medicines that improve the lives of people 
around the world while educating and training a 
workforce that will perpetuate this public health 
mission. 
 
Over 120 Years of Evolution in Discovery and 
Manufacturing Technologies 
1894-1946 
 
 
 
 
 
• The State Labs, part 
of the Massachusetts 
Department of Public 
Health, focused on 
Equine antitoxins.  
• Issued License #64 
for producing 
smallpox vaccine and 
diphtheria antitoxin 
1946-1997 
 
 
 
 
 
• The State Labs 
become the State 
Laboratory for 
Plasma Fractionation 
and continues as part 
of the Massachusetts 
Dept. of Public 
Health.  Focus 
changes to producing 
therapeutics from 
human serum. 
1997-Present 
 
 
 
 
 
• In 1997 the State 
Legislature transfers 
oversight to 
University of 
Massachusetts 
Medical School . 
• MassBiologics 
manufactures 
vaccines and human 
monoclonal 
antibodies. 
2014- 
 
 
 
 
 
• cGMP Vector 
Manufacturing 
Center (VMC) 
awarded by 
Commonwealth of 
Massachusetts 
• MassBiologics  
manufactures 
viral/plasmid 
vectors with single 
use bioreactors 
 
Evolution of Products 
1894-1946 
 
 
 
 
 
• Diphtheria Antitoxin-
Equine 
• Botulism Antitoxin-
Equine 
• Tetanus Antitoxin-
Equine 
• Rabies 
Immunoglobulin-
Equine 
 
1946-1997 
 
 
 
 
 
• Human Serum 
Albumin 
• Human Immune 
Globulin 
• Human Hyper-
Immune Globulin to: 
– Scarlet Fever 
– Pneumococcus 
– Meningococcus 
– Tetanus 
– Measles 
– CMV 
– RSV 
– Varicella-zoster 
– Rabies 
– Hepatitis A 
 
1997-Present 
 
 
 
 
 
• Td Vaccine 
• Human Monoclonal 
Antibodies against 
• SARS  
• C diff Toxins A and B  
• Rabies 
• Hepatitis C 
• Tet and Diph Toxins 
• SOD1 for ALS 
• sFlt-1 for Pre-eclampsia 
New Targets 
Contract 
Manufacturing 
 
2014- 
 
 
 
 
 
• rAAV vectored huMabs 
and therapeutic 
biologicals 
• Plasmids for transient 
vectoring of huMabs 
 
Products in Clinical Trials 
• C. dificile anti toxin A/B Phase III Clinical Trial 
– Prevent recurrent CDAD 
– Licensed to Merck 
• HCV Monoclonal Antibody (mAb) in Clinical Trials 
– Ongoing Phase 2 mAb + DAA in Liver Transplant Patients 
– Granted orphan-drug designation by the FDA (Nov 2013 ) 
•  “prevention of hepatitis C recurrence in patients receiving liver 
transplantation” 
• Phase 2/3 Rabies mAb Trial ongoing in India 
– 185/200 patients with exposure to potentially rabid animal randomized to HRIG + 
vaccine or Rabies mAb + vaccine 
– Pivotal trial for registration (licensure) in India  
• Diphtheria anti-Toxin mAb in Preclinical Development 
– MCB produced and released Sept 2013 
– mAb potency assignment finalized September, 2014 
What Do You Need To Consider To Develop A Medicine 
  Pre-Clinical     Phase I       Phase II  Phase III 
4.3 Years 1.6 Years 2.4 Years 2.7 Years 
11 Yrs 
Uniform New Medicine Evaluation Template 
UNMET Need for Medicine for Better Lives 
CATEGORY EVALUATION CRITERIA RATING (Color) 
Target 
Green = Well defined, well reasoned target 
Amber = Pseudo-defined; reasoning not thoroughly thought out/presented 
Red = Nebulous; no rationale for selection   
Therapeutic Indication 
Green = Clear therapeutic/prophylactic indication 
Amber = Poorly defined/debatable therapeutic/prophylactic indication 
Red = Diagnostic, imaging agent   
Uniform New Medicine Evaluation Template (cont.) 
FEASABILITY OF GENERATING 
AND EVALUATING A mAb EVALUATION CRITERIA RATING (Color) 
Immunogen* 
Green = Fully identified or minimal work needed to identify completely/specific 
Amber = Minimal work needed to identify completely/may be an issue with specificity; or 
identified/non-specific; or Early stage of identification; some data available 
Red = Unknown 
  
Availability of immunogen* 
Green = Readily available from a commercial source; or able to generate in-house easily 
Amber = Available from a commercial source but expensive; or able to generate in-house 
with difficulty or expensive 
Red = Not available; IP costs prohibitive or not available for licensing 
  
In vitro assays to assess 
functionality 
Green = Assay(s) developed or assay(s) in development; body of data to support relevance 
Amber = Assay(s) in development; promising but not enough data to support relevance 
Red = No ability to develop a relevant model 
  
In vivo model for efficacy 
Green = Small animal model(s) developed and accepted as standard 
Amber = Large animal model developed and accepted as standard but expensive; or small 
animal model with data to support relevance 
Red = No ability to develop a relevant model 
  
* If a MAb has already been generated by the respondent the section is N/A 
Uniform New Medicine Evaluation Template (cont.) 
PRECLINIAL DATA EVALUATION CRITERIA RATING (Color) 
Literature 
Green = Paper(s) indicate feasibility of MAb approach against the target; quality of research 
not in question 
Amber = Minimal information or quality of research paper questionable 
Red = Literature indicates MAb approach against target is not feasible 
  
In vitro data 
Green = Substantial data from a relevant model 
Amber = Minimal data from a relevant model 
N/A = No data as not at that stage of development   
In vivo data 
Green = Substantial data from a relevant model 
Amber = Minimal data from a relevant model 
N/A = No data as not at that stage of development   
Toxicology 
Green = Clean tox and/or cross-reactivity data 
Red = Tox and/or cross-reactivity data with issues 
N/A = No data as not at that stage of development   
Uniform New Medicine Evaluation Template (cont.) 
CLINICAL TRIAL FEASIBILITY EVALUATION CRITERIA RATING (Color) 
Patient population and potential 
impact 
Green = > 200,000/year in US; or > 200,000/year in US and ROW1; or small patient 
population but large impact on morbidity/mortality 
Amber = 10,000 - 200,000 in US and/or ROW 
Red = < 10,000/year in either US or ROW or only in ROW; or large population but minimal 
impact on morbidity/mortality 
  
Ethics 
Green = No ethical concerns; or ethical concerns; able to overcome by using animal 
effectiveness rule (21 CFR 601.90) - relevant model(s) readily available 
Amber = Ethical concerns; able to overcome by using animal effectiveness rule - relevant 
model(s) available on a limited basis or are in early stage of development/promising data 
Red = Ethical concerns/unable to use animal effectiveness rule - no animal model possible 
  
Risk of adverse effects 
Green = No known risk 
Amber = Risks theoretical or likely by dose 
Red = Likely risk for a serious outcome   
Study size/cost (Phase II) - based 
on measurable and clinically 
significant primary endpoint 
Green = ≤ 200 subjects; ≤ 2 years 
Amber = 200 - 500 subjects; 2 - 4 years 
Red = > 500 subjects or > 5 years 
  
Uniform New Medicine Evaluation Template (cont.) 
MARKET EVALUATION CRITERIA RATING (Color) 
Worldwide market 
Green = > $1 billion 
Amber = $50 million to $1 billion 
Red = < $50 million   
Alternate therapies (licensed) 
Green = None; or available but not highly effective 
Amber = One used on or off-label 
Red = > one; highly effective; no problems with supply   
COMPETITION EVALUATION CRITERIA RATING (Color) 
In development 
Green = None (drugs, MAbs, or biologics) 
Amber = MAbs or non-MAb(s) in early stages (Preclinical, Phase I/II) 
Red = MAA2 (drugs/MAbs/biologics) in final stages of review 
  
IP Concerns 
Green = None; or patents pending - likely to have no issues with claims 
Amber = Patent(s) pending - claims could be restrictive 
Red = Freedom to operate and/or prior art issues; or patent applications not filed 
  
Uniform New Medicine Evaluation Template (cont.) 
BUSINESS AND 
COLLABORATION 
OPPORTUNITIES 
EVALUATION CRITERIA RATING (Color) 
Ability to collaborate 
Green = Part of UMass; no affiliations/agreements with outside entities re. target or one(s) 
that MBL could enter 
Amber = Inventor(s) are founder(s) of start-up company; or Potential collaborator 
negotiating with third party 
Red = Restrictive agreements/IP issues 
  
Type of collaboration 
Green = Full partnership 
Amber = Scientific and/or investment and/or clinical 
Red = In-licensing; cost prohibitive   
UMass - collaboration would 
enhance scientific knowledge 
Green = UMass Medical School 
Amber = UMass affiliated 
N/A = Not part of UMass; or collaboration would not enhance scientific knowledge 
  
Scientific/clinical 
Green = Respected leader in scientific or clinical field and/or unique models/assays/facility 
for performing or developing such assays 
Amber = Capable hands to share workload; or inventor(s) are founder(s) of a start-up 
Red = Nothing outside of target 
  
1ROW - Rest of World 
2MAA - Marketing Authorization Application (eg BLA, NDA in US) 
Uniform New Medicine Evaluation Template 
UNMET Need for Medicine to Prevent Lyme Disease 
CATEGORY EVALUATION CRITERIA RATING (Color) 
Target Borrelia burgdorferi 
  
Therapeutic Indication 
monoclonal antibody for passive immunization against Borrelia burgdorferi, the causative 
agent of Lyme disease 
 
administered annually, prior to beginning of tick-exposure season 
-- seek initial licensure in adult, then in pediatric population   
“UNMET” Evaluation for a mAb to prevent Lyme 
Disease 
Pre-Clinical 
feasibility 
  overall: for passive protection, OspA is a validated immunogen for human protection and provides a clear path 
 
  
Immunogen: 
identified OspA antibodies can provide passive protection (no treatment once disease acquired)   
availability can be recombinantly expressed   
antigen IP possibly, if antigen is used for a recombinant vaccine 
 
composition IP on antibody generated against antigen possible 
  
functional assay(s) yes, can perform a bactericidal assay with bacteria, antibody, complement and fluorescent stains   
in-vivo model yes, mouse model for acute disease and model of antibiotic refractory arthritis are available   
toxicology (acute vs. chronic) looking to dose subjects only once, but maintain protection sufficient for approximately 4 months - we would need to 
ask/confirm with agency about duration of tox monitoring (1 dose with 1 month study sufficient?) 
 
if plan is to give a single dose to subject 1x/season but every year, would need to do tox studies with repeated doses 
in mice to maintain serum levels and again, need to ask/confirm with agency about duration of tox follow-up 
  
execution of project: 
biohazard level biohazard level 2   
facilities needed standard lab facilities. If performing animal tick transfer experiment, may need to maintain a tick colony   
collaborators MBL Executive Vice Chancellor is a Lyme expert with many connections in the field   
background 
literature 
(supports target 
rationale; in-vitro/in-
vivo data to support 
target) 
very clear animal work in several species to support passive protection. Crystal structure of target protein (OspA) with 
bound neutralizing antibody (LA-2) 
  
“UNMET” Evaluation for a mAb to prevent Lyme 
Disease 
regulatory: 
animal rule applicable? no   
US or ROW (guidelines to be aware 
of, including any 
relating to combination 
trials) 
path to licensure of vaccine straightforward   
SOC (trial design compatible 
with standard of care) 
SOC is antibiotic course after diagnosis or probable diagnosis - antibody drug should have no effect on the treatment   
dose: (mode of delivery) IM preferable over IV. 
Based on previous OspA LA-2 equivalent epitope competitive ELISAs to quantitate LA-2 Elisa titer - predictive 
protective levels estimate dose at around 20 mg dose for a 70 kg individual with an antibody with a 1 month half-life 
to have higher than 0.4 ug/ml at end of tick season 
--however, some data showing breakthrough with <1000ng/ml level, so may need to confirm higher dose not 
required for complete protection 
  
Making a mAb Medicine 
Key Components 
Drug Discovery 
Process 
Development 
Preclinical 
Safety & Efficacy 
Regulatory 
Affairs and 
Business 
Development 
Good Manufacturing 
Practice and Quality 
Controlled Drug 
Product 
Clinical 
Studies 
Product Discovery 
• Responsible for identification and selection of 
Human Monoclonal Antibodies 
– Monoclonal antibody isolation, transgenic mice, B-cell 
cloning 
– Develop screening assays for binding and in-vitro potency 
– Characterize leads: Heavy and light chain sequence, affinity, 
epitope mapping 
– Develop/Test leads in animal models of disease 
– Manage and lead teams of Research Associates and 
Scientists 
 
Process Development Activities 
• Upstream process development 
– Cell line, medium, and bioreactor process 
• Downstream process development 
– Purify proteins 
• Analytical method development 
– Characterize proteins 
• Formulation development 
– Safe and stable formulations 
• Develop, optimize, scale-up manufacturing processes 
• Preclinical material production and technology transfer to 
GMP manufacturing facility 
Mammalian Cell Culture Development 
• Full support from transfection to pilot production 
• Cell line characterization 
• Master & working cell bank creation 
• 1L Bench top bioreactors (DasGip & Applikon) 
• Wave disposable bioreactors (2-20L) 
• Scale up bioreactors (10L & 60L Applikon) 
Cell Culture Development 
Benchtop Bioreactors 
Pilot Scale Production  
60L Scale up bioreactor 
Analytical Method Development 
 Purity/impurity profiles 
 Peptide mapping 
 Carbohydrate analysis 
 Concentration 
 ELISA 
 Host cell protein 
 Host cell DNA 
 Activity 
 Kinetic/binding assays 
 Spent media analysis 
 
Preculture 100L 
Bioreactor 
500L 
Bioreactor 
2,000L 
Bioreactor 
10,000L 
Bioreactor 
Vial 
CIP/SIP 
 
Cation 
Exchange 
 
 
Anion 
Exchange 
 
Virus Filter 
Fill 
Release 
0.2µm filter 
Medium 
Buffer 
Virus Inactivation 
 
Capture 
Column 
 
 
Dia-
filtration 
 
Manufacturing Process for MAbs 
Centrifugation 
20L 
Bioreactor 
Formulate 
 GMP BDS Manufacturing 
55L & 500L Bioreactors 
MassBiologics 
GMP BDS Manufacturing 
2500L Bioreactor & Harvest Tank 
MassBiologics 
 GMP Fill/Finish Manufacturing 
Bosch Fill Line 
Quality 
• Quality Assurance:  
Responsible for assuring that appropriate procedures exist,  
are followed in a document manner and investigating and  
evaluating deviations from  such procedures.  
– Independent of manufacturing [21 CFR §211.22] 
– Write what you do : Do what you write  
– SOPs, BRs, standard forms, verifications, reviews 
• Quality Control:   
Responsible for checking quality of starting, intermediate and finished 
materials 
– Water, clean room environments, incoming chemical and consumables 
– Safety, Purity and Potency of drug intermediates, bulk and final vial 
product  
– Microbiology, Chemistry, Biochemistry, Bioassay (in vitro and in vivo) 
 
Validation and Quality Systems 
• Validation:  
Responsible for proving that (engineering) systems  
perform consistently within specification: 
– sterilization, depyrogenation, temperature controlled units, HVAC etc.. 
– written protocols, new systems/periodic reviews/change management 
– FDA mandated for licensed product and “safety” systems for CTMs    
 
• Quality Systems: 
– Management of Controlled Documents – paper and virtual 
– cGMP archive system (statutory record retention) 
– Validation of cGMP computerized systems 
– Operation of validated clinical data management systems  
 
 
 
 
 
Regulatory 
• Compile/file Investigational New Drug applications (INDs) 
• Maintain Biologics License Application   
• Write and file license and IND supplements 
• Manage day-to-day and strategic relationship with FDA 
• Participate in internal projects to gauge and manage regulatory impact  
 
How do we communicate to the FDA that: 
• our products/processes are safe & appropriate for clinical trial subjects  
 
OR, for pivotal trials/licensed products,  
• safe in patients  
• effective for their intended/labeled indications  
 
Business Development of New Medicines 
• Overview of role: 
– Protection of asset: contracts, patents, disclosure review for 
inadvertent or premature disclosure of IP    
– Commercialization of asset: identify competitors and 
collaborators, strength/weakness of product, 
regulatory/reimbursement isues; source collaborators/funding for 
translational work; negotiate MTAs, research, and clinical trial 
agreements 
– Management of asset: maintain issued patents; manage 
collaborations to maximize benefits; re-negotiate/terminate  contracts 
that no longer meet objectives; continued monitoring of competitive 
landscape related to products  
Development of a High Cell Density Fed-batch Insect-cell Based 
Process Platform  
Joshua Merritt*, Megan Dempsey*, Lindsay Hock*, Christina Paul*, Elyse Tanzer*, Yang Wang**, Tuhina Bhattacharya*, and Sadettin Ozturk*  
*Process Development and **Product Discovery, MassBiologics of the University of Massachusetts Medical School, 460 Walk Hill Street, Mattapan MA 02126 
MassBiologics is currently developing a high cell density fed-batch insect-cell based process platform 
for the production of proteins, virus-like-particles and viruses for use as human therapeutics.  In order 
to achieve this end, the impact of feeding three different types of nutrient pools on Sf9 cell culture 
growth was tested using a design-of-experiments (DOE) approach.  In the ranges tested, yeastolate 
and MassBiologics’ chemically defined feed (F-19, a protein-free mixture of amino acids, vitamins, 
trace minerals and other cell culture nutrients) both individually and combinatorially increased 
maximum culture cell densities while a chemically defined lipids mixture had no significant impact.  A 
yeastolate feed rate was identified above which the maximum cell density obtained was reduced, 
putatively, due to toxic metabolic by-product accumulation. Maximum cell densities increased with 
increasing feed rates of MassBiologics’ chemically defined feed.  Spent medium analysis indicated 
depletion of several amino acids during the shake flask screen.  The feed medium was supplemented 
with these amino acids and modified feeds and feed rates based on the shake flask experiment were 
implemented in a 1 L scale bioreactor experiment.  The highest cell densities obtained during this 
experiment were approximately 3-fold higher than those obtained in an unfed bioreactor culture: 
35.9 x 106 cells/mL vs. 12.0 x 106 cells/mL.  Rates of baculovirus infection at various cell densities were 
measured using a green fluorescent protein expression assay.  
Abstract 
Shake flask fed-batch cultures: Flasks were seeded at 5e5 cells/mL , and fed daily when the VCD 
reached 5-10e6 cells/mL.  Flask pH and glucose concentrations were adjusted daily based on off-line 
measurements. Daily cell counts and metabolite measurements were performed. 
Bioreactor cultures: Bioreactor experiments were performed in 1L DASGIP bioreactors.  Cultures 
were fed continuously with  a mixture of chemically-defined feed and lipid; yeastolate was batch-fed 
daily.Feeding was initiated when VCD was around 4e6 cells/mL. 
Amino acid analysis: A spent media analysis was performed using Ultra Performance Liquid 
Chromatography to determine the amount of amino acids in the shake flask and bioreactor cultures. 
Green fluorescent protein (GFP) expression: Three 1L DASGIP bioreactors were seeded at 1e6 
cells/mL and continuously fed daily with 1.5% feed, 1% yeastolate, and 0.25% lipid beginning when 
VCD reached 4e6 cells/mL. The first bioreactor served as the control condition, the second was 
infected with GFP-producing baculovirus at an MOI of 2.5 when VCD reached around 8e6 cells/mL, 
and the third bioreactor was infected at the same MOI when VCD  reached 17e6 cells/mL. 
Immediately post-infection, culture was removed from the reactors  and used to seed shake flasks at 
2e6 cells/mL in fresh medium. Daily cell counts and metabolite analysis were performed on all 
bioreactors and shake flasks . The percentage of infected cells (GFP expression) was measured each 
day post-infection using a Guava flow cytometer. 
Methods 
Using a DOE approach and leveraging in-house analytical capabilities MassBiologics has developed a 
high cell density fed-batch process for growing Sf9 insect cells.  In  bioreactors, the process  resulted 
in a VCD increase of about 300% relative to unfed bioreactor cultures.   
 
Initial infection (GFP-expressing baculovirus) and protein expression experiments  indicate that cells 
can be efficiently infected in bioreactors at a VCD of about 8e6 cells/mL but that infection in this 
system at a VCD of about 17e6 was inefficient.  Differences in infection rates between bioreactors and 
flasks seeded with post-infection cells from the bioreactors indicates that conditions inside the 
bioreactors are suboptimal for baculovirus infection in a yet-to-be defined way. 
 
Subsequent work will focus on optimizing bioreactor conditions conducive to baculovirus infection 
and the associated protein expression.  For example, high rates of CO2 gassing were required to 
maintain pH in the desired range (pH<6.4) in mid to late culture and, as a result, high rates of 
dissolved CO2 were observed (data not shown, previously demonstrated to be growth-inhibitory); an 
alternative pH control strategy is currently being formulated.  It is also anticipated that post-infection 
feed rates will require optimization since the current feed rates were appropriate for rapidly growing 
rather than quiescent, infected cultures.      
Conclusions & Future Work 
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Culture Lactate Concentration
F-19 = 0.5 or 1.0
Yeastolate = 2
F-19 = 0 or 0.5
Yeastolate = 1
F-19 = 0.5 or 1.0
Yeastolate = 1
Amino 
Acid F0,Y1,L0.25 F0,Y1,L0.5 F0,Y2,L0.25 F0,Y2,L0.5 F0.5,Y1,L0.25 F0.5,Y1,L0.5 F0.5,Y2,L0.25 F0.5,Y2,L0.5 F1, Y1, L0.25 F1, Y1, L0.5 F1, Y2, L0.25 F1, Y2, L0.5
Hypro 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1
His 1.4 1.5 1.8 2.0 1.4 1.3 2.0 2.3 1.3 1.4 2.5 1.9
Asn 1.0 1.1 1.1 1.2 1.2 1.1 1.2 1.4 1.1 1.2 1.5 1.3
Tau 0.8 0.9 1.2 1.1 1.0 0.9 0.9 1.0 1.9 2.0 1.8 1.8
Ser 0.0 0.0 0.5 0.7 0.0 0.0 0.7 0.9 0.0 0.0 1.1 0.6
Gln 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Arg 1.6 1.7 2.6 2.9 1.7 1.4 2.9 3.4 1.6 1.8 3.5 2.5
Gly 10.7 11.6 17.9 20.2 10.3 9.2 18.9 22.3 8.8 9.1 22.0 16.1
Asp 1.3 1.3 1.2 1.3 1.1 1.0 1.4 1.6 1.1 1.1 1.7 1.7
Glu 1.3 1.4 1.3 1.3 1.7 1.5 1.4 1.7 1.4 1.4 1.7 1.5
Thr 1.1 1.2 2.2 2.4 1.3 1.2 2.6 3.1 1.4 1.5 3.2 2.6
Ala 51.9 60.8 58.2 55.0 62.0 46.7 51.3 59.4 55.8 65.1 54.4 48.2
Pro 1.5 1.6 1.8 2.0 1.7 1.4 2.1 2.4 1.6 1.7 2.4 2.0
Cys 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1
Lys 1.0 1.1 1.5 1.6 1.2 0.9 1.7 2.1 1.1 1.2 2.0 1.6
Tyr 0.4 0.4 0.7 0.8 0.5 0.4 0.9 1.0 0.5 0.5 1.2 0.8
Met 4.5 4.9 5.0 5.2 4.9 4.3 5.2 5.9 4.4 4.8 5.7 5.1
Val 1.0 1.1 1.5 1.5 1.1 1.0 1.6 1.9 1.1 1.2 1.9 1.6
Ile 1.0 1.1 1.3 1.3 1.3 1.1 1.5 1.7 1.2 1.3 1.7 1.5
Leu 0.2 0.3 0.7 0.7 0.4 0.3 0.8 1.0 0.4 0.5 1.0 0.9
Phe 6.3 6.8 7.2 7.4 6.7 6.1 7.4 8.4 6.2 6.5 8.3 7.4
Trp 0.6 0.7 1.0 1.1 0.8 0.7 1.2 1.4 0.8 0.9 1.5 1.2
F19 Feed 
Rate
Yeastolate Feed Rate Lipid Feed Rate
Max VCD (cells/mL) 
Flask 1
Max VCD (cells/mL) 
Flask 2
0 0 0 1.26E+07 1.25E+07
0 1 0.25 1.97E+07 1.82E+07
0 1 0.5 1.79E+07 1.82E+07
0 2 0.25 1.91E+07 2.03E+07
0 2 0.5 1.85E+07 1.80E+07
0.5 1 0.25 2.53E+07 2.59E+07
0.5 1 0.5 2.55E+07 2.76E+07
0.5 2 0.25 2.36E+07 2.22E+07
0.5 2 0.5 2.14E+07 2.21E+07
1 1 0.25 2.80E+07 2.89E+07
1 1 0.5 2.76E+07 2.74E+07
1 2 0.25 1.92E+07 2.03E+07
1 2 0.5 2.25E+07 2.54E+07
Shake Flask Full-factorial Feed Development Experiment 
Figure 1. (Top) 3-factor, 2 or 3 level full-factorial DOE designed to elucidate the impact of different feeds on 
maximum cell density in Sf9 shake flask culture.  (Bottom) JMP leverage plots show that, in the ranges 
tested, yeastolate and MBL’s chemically defined feed (F-19) significantly (p<0.05) impact culture maximum 
viable cell density. 
Figure 2. (Top) In addition to  increasing or decreasing maximum viable cell density in Sf9 cultures, 
different feed combinations impacted culture longevity.  (Bottom) Results of spent medium analysis at Day 
11 indicate that specific amino acids (Ser, Gln, Cys) were depleted from some cultures and, thus, 
subsequent media formulations should be enriched in these components. 
Figure 3. Increased rates of lactate (Top) and ammonia (Bottom) appear to be associated with the higher 
rate of yeastolate feed used in this experiment.  Because yeastolate addition is required for optimal 
growth  using the current feed strategy (Figure 1 and Figure 2), it’s feed rate will require optimization in 
subsequent experiments.. 
Bioreactor Confirmation and Infection Experiments 
Figure 4. Growth (Top) and culture viability (Bottom) of 1 L bioreactor fed-batch and unfed cultures.  The 
maximum VCD of cultures fed with MBL’s chemically defined feed, yeastolate and a defined lipids mixture 
were about 3-fold higher than that of the unfed culture grown under otherwise identical conditions.  These 
results further indicate that the correct combination of the three feeds is required for maximal growth.  
Figure 5. Potentially toxic lactate (Top) and ammonia (Bottom) accumulation were minimized by feeding 
cultures properly.  Higher rates of accumulation occurred, in some cases, after Day 9 when culture growth 
had ceased. 
Figure 6. Growth (Top) and percentage of cells expressing GFP (Bottom) of infected and non-infected 1L 
bioreactor (DG) and shake flask (SF) cultures.  The bioreactor infected at about 8e6 cells/mL and the shake 
flask derived from it infected more quickly (shake flask) and to a higher degree (bioreactor) than those 
infected at about 17e6 cells/mL.  Optimization of this procedure will be subject of future experiments. 
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